Jaguar Health (JAGX) Stock Plunges 28% After Historic 1,190% Surge on FDA News

Key Takeaways

Table of Contents

JAGX shares declined approximately 28% in Wednesday’s premarket session to around $24.82 following Tuesday’s massive 1,190% gain.
The previous day’s explosive move was triggered by FDA fee waivers for Mytesi and Canalevia-CA1 combined with aggressive retail buying.
The company executed a 1-for-15 reverse split in mid-September, resulting in approximately 520,000 shares outstanding.
While the fee waivers lower regulatory expenses, they don’t signify new product authorization.
The biotech firm plans a mid-2027 submission for crofelemer in pediatric microvillus inclusion disease treatment.

Shares of Jaguar Health (JAGX) experienced a dramatic reversal Wednesday morning, declining roughly 28% in premarket activity to approximately $24.82. This pullback came on the heels of Tuesday’s remarkable 1,190% spike, which saw the stock rocket from $2.67 to finish at $34.46.

Jaguar Health, Inc., JAGX

Initial premarket reports showed JAGX climbing an additional 11%, but that advance quickly evaporated. The wild price swings underscore the company’s minimal float following its recent reverse split and heightened speculative activity from retail traders.

The biotech company implemented a 1-for-15 reverse stock split on September 17 to maintain Nasdaq compliance standards. According to an SEC disclosure, Jaguar had roughly 520,088 common shares in circulation immediately post-split.

Fee Waivers From FDA Ignited Tuesday’s Explosive Move

The primary catalyst behind the price action was regulatory news. Jaguar announced its Napo Pharmaceuticals subsidiary secured a fiscal year 2027 Prescription Drug User Fee Act exemption for Mytesi, while the FDA’s Center for Veterinary Medicine granted similar relief for Canalevia-CA1.

Mytesi has existing approval for managing noninfectious diarrhea in HIV/AIDS patients undergoing antiretroviral treatment. Canalevia-CA1 holds conditional approval for treating chemotherapy-related diarrhea in canines.

These waivers eliminate certain fees tied to the currently marketed products. It’s crucial to note these are not new drug approvals or positive trial outcomes.

Future Pak commercializes both products domestically through a licensing agreement, while Jaguar handles manufacturing and distribution.

Rare Disease Development Represents Core Growth Strategy

Jaguar is shifting strategic emphasis toward developing crofelemer for uncommon gastrointestinal conditions. The primary focus involves MVID, a severe intestinal condition that often requires children to rely on intravenous nutrition and hydration.

According to Jaguar, all randomized pediatric participants in its MVID trial are advancing to an extension study. The company has documented as much as a 48% decrease in intravenous support requirements for one patient following prolonged crofelemer administration.

The company anticipates filing a new drug application for MVID by mid-2027. Jaguar is simultaneously seeking a development and commercialization collaboration partner for this pipeline candidate.

The major warning for investors is exceptional volatility. JAGX continues to operate as a small-cap biotechnology firm with a track record of reverse splits, operating losses and capital requirements, while Tuesday’s price explosion vastly exceeded the financial benefit of the fee waivers themselves.

Wednesday’s steep decline underscores these hazards. Market participants are now weighing the rare disease potential against a severely limited share float, dilution risks and highly speculative trading behavior.

✨ Limited Time Offer